A phase 3, randomized, double-blind, multicenter study of talabostat and pemetrexed [Alimta; Eli Lilly] vs. pemetrexed and placebo in patients with advanced (stage IIIB/IV) non-small cell lung cancer (NSCLC) after failure of platinum-based chemotherapy
Latest Information Update: 19 Sep 2007
At a glance
- Drugs Pemetrexed (Primary) ; Talabostat (Primary)
- Indications Non-small cell lung cancer
- Focus Registrational; Therapeutic Use
- Sponsors Point Therapeutics
- 22 May 2007 Status change
- 10 Feb 2006 New trial record.